Huma’s $130m raise will scale its digital health platform

Latest articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

X marks the spot for meaningful information on aging and cognition

Understanding chromosomal differences between men and women could be the X Factor when it comes to tackling cognitive decline. A new paper published in Jama...

Most read

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Editor's picks

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

Buck researchers provide a framework to study precision nutrigeroscience

One size doesn't fit all – a new research sub-specialty deals with the fact that health benefits from many forms of dietary restriction vary...

Accelerating antiaging research by hacking longevity

Bringing together aging researchers, developers and entrepreneurs, the Longevity Hackathon aims to build new tools, raise awareness and attract talent to the field. Kicking off...

Click the globe for translations.

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies.

The investment arms of Bayer, Hitachi, Samsung, Sony Innovation Fund by IGV, Unilever and the PE fund HAT are financing Huma Therapeutics Ltd to the tune of approximately $130 million.

Longevity.Technology: This sizeable investment will scale Huma’s modular platform which can power digital ‘hospitals at home’ nationally, and support the pharmaceutical and research industries to run the largest ever decentralised clinical trials. Huma’s platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research and expand their presence globally after last year’s acquisition of AI and wearables companies Biobeat and Tarilian Laser Technologies.

As interventions lead to longer lifespans and an aging population, aging in place continues to gather investment and inform strategy at a government level; Longevity.Technology is preparing a market intelligence report on the sector, and this is available to pre-order.

Leaps by Bayer and Hitachi Ventures led the Huma Series C funding round, which also saw new strategic and financial investors become shareholders. Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as individuals Nikesh Arora (former president of SoftBank) and Michael Diekmann (Chairman of Allianz) are also new shareholders.

Huma
Huma’s digital ‘hospital at home’

A further commitment of $70 million that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200 million. Goldman Sachs International acted as lead placement agent to Huma. HSBC Bank plc and Nomura acted as joint placement agents, with the latter also becoming a shareholder.

 


 

This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives.”

 


 

The new investment will be used to expand Huma’s digital platform in the US, Asia and the Middle East, with Huma having recently been named Europe’s fastest growing healthcare company by the Financial Times. Huma has an established health technology and innovation partnership with four national governments (England’s NHS, Wales, Germany and UAE). Its digital ‘hospital at home’ was co-created with clinicians and has been independently shown to almost double clinical capacity, reduce hospital readmissions by over a third and has patient adherence levels of over 90%. The service is supporting governments’ pandemic responses on a not-for-profit basis and is now used for a range of patients including those going through knee- and hip-replacement surgery, for example with Smith+Nephew.

Ovarian Longevity webinar

Huma
The ‘hospital at home’ mobile app.

Huma advanced its work in the US in 2021, fostering new partnerships with clinical research organisations, health care providers, payers, research organisations and tech companies.

Dan Vahdat, Founder and CEO of Huma, said: This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives. We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago. Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide [1].’’

Alan Milburn, former UK Health Secretary and Chairman of Huma’s Board, said: “This is a significant moment in Huma’s history and I will work to build enduring, trusted relationships with our new partners. We are living through unprecedented times and the importance of health and well-being is underlined as never before. Together with our partners we can use our expertise, technology, and innovation to change the face of healthcare and research and impact people’s health everywhere [1].”

Huma’s ambition to improve people’s health across the world will be accelerated with its new global partnerships. Juergen Eckhardt, Head of Leaps by Bayer, commented: “Aligned with the vision of Leaps by Bayer, Huma’s expertise and technology will help drive a global paradigm shift towards prevention and care and may boost research efforts using data and digital technology. We invest into the most disruptive technologies of our time that have the potential to change the world for the better. As an early investor into Huma we know how perfectly the company fits into that frame as one of the leading digital innovators in healthcare and lifesciences [1].”

Ovarian Longevity webinar

[1] https://info.huma.com/financing-announcement

Images courtesy of Huma
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Berberine could be longevity’s “best-kept secret”

From tackling senescence to lowering blood sugar, berberine is the supplement with a host of tricks up its sleeves. Berberine is a bioactive compound found...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...

Related articles

Peptide therapeutics company targets age-related disease

Gray Matter working with Insilico Medicine to identify peptide targets and accelerate development timeline for age-related disease therapies. Earlier this month, we brought you the...

SENS spin-out Underdog closes $10m financing round

Underdog Pharmaceuticals, a key investment of rejuvenation biotech VC Kizoo, has closed a $10 million round of capital. Michael Greve’s Kizoo Technology Capital Group led the...

Unlocking ovarian aging could prolong fertility and delay menopause

Ovarian aging is poorly understood, under-researched and under-invested. We need a radical rethink of how we address fertility and the menopause – it's time...

Occuity raises over £2.5m for optical diabetes devices

UK MedTech firm Occuity successfully raises over £2.5m to deliver ophthalmic and optical diabetes devices and is now overfunding on Seedrs to accelerate development. DISCLOSURE:...

Fauna closes $9 million to expand drug discovery platform

Leveraging animal genomics to improve human health, Fauna Bio set to expand its comparative genomics platform for novel target drug discovery. Silicon Valley biotech startup...
Nutriop